None listed
Conditions
Interventions
This study will compare the short term bioavailability of 3 delivery systems containing omega-3 oils. They are (1) gel capsules versus (2) MicroMAX 1 powder – formulated with milk protein-sugar versus (3) MicroMAX powder - formulated with milk protein-sugar-resistant starch) when combined with a flavoured milk in individuals. Bioavailability will be assessed by measurement of EPA & DHA in blood/plasma.
This is a crossover design study in which all participants will receive the three treatments
This study will compare the short term bioavailability of 3 delivery systems containing omega-3 oils. They are (1) gel capsules versus (2) MicroMAX 1 powder – formulated with milk protein-sugar versus (3) MicroMAX powder - formulated with milk protein-sugar-resistant starch) when combined with a flavoured milk in individuals. Bioavailability will be assessed by measurement of EPA & DHA in blood/plasma. This is a crossover design study in which all participants will receive the three treatments with a washout period of 6 weeks between each treatment. To investigate the bioavailability of a single dose of omega-3 oils delivered via the three above mentioned formats over 48 hrs. The two different MicroMAX powders (one formulated with milk protein-sugar and other milk protein-sugar-resistant starch) will each be provided as an 8g serve containing a dose of 500mg/g omega-3 oil. The gel capsules will be given as a one-off dose of 4 capsules (each capsule will contain 1000mg of omega-3 oil).
Sponsors
CSIRO Preventative Health Flagship
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Educational / counselling / training
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male and Females aged between 18-70 years 2. Normal dietary habits (no medically prescribed diet, no slimming diet, and no vegan or macrobiotic diet). 3. Body Mass Index >18 kg/m2 < 35kg/m2 4. Apparently healthy: no reported current or previous metabolic diseases, gastrointestinal disorders, renal or cardiovascular disease. 5. Person having given their specific consent in writing.
Exclusion criteria
1. Regular use of supplements containing omega-3 essential fatty acids must have ceased 2 months prior to the start of the study. 2. Regular consumption of foods supplemented with omega-3 essential fatty acids such as some breads and milk products 3. Consumption of fish as part of regular dietary patterns 4. Current relevant medical treatment (subject to judgement of the investigator). 5. High alcohol consumption (>21 standard drinks/week) 6. Reported participation in another biomedical trial 3 months before the start of the study or during the study. 7. Food allergies or intolerances (dairy, lactose, peanuts, shellfish, etc…). 8. Recent history (within 12 months) of substance abuse including alcohol abuse.
Outcome results
None listed